Since accumulating studies have confirmed that TGF-β/Smad3 signaling plays extensive regulatory roles in the development and progression of multiple types of cancers, we next conducted Western blot assays to assess the effects of SCRN1 knockdown on the activity of TGF-β/Smad3 signaling. This evidence concerns the gene SCRN1 and cancer.